FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says
December 30, 2022 at 11:21 AM EST
A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with irregularities."
